The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2026

Filed:

Dec. 23, 2022
Applicant:

Bostongene Corporation, Waltham, MA (US);

Inventors:

Nikita Kotlov, Limassol, CY;

Georgy Sagaradze, Moscow, RU;

Alexander Bagaev, Waltham, MA (US);

Grigorii Nos, Moscow, RU;

Lev Begniagin, St. Petersburg, RU;

Dmitry Kravchenko, Yerevan, AM;

Anna Gribkova, Moscow, RU;

Assignee:

BostonGene Corporation, Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G16B 40/00 (2019.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); G16B 30/00 (2019.01);
U.S. Cl.
CPC ...
G16B 40/00 (2019.02); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2018.01); C07K 16/2887 (2013.01); G16B 30/00 (2019.02); A61K 2239/48 (2023.05); C07K 2317/24 (2013.01);
Abstract

Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subjects prognosis based upon the LME type determination.


Find Patent Forward Citations

Quick Actions:

Kotlov, Nikita. (2026). Tumor microenvironment-based methods for assessing car-t and other immunotherapies (U.S. Patent No. 12580049). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12580049

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…